Tegaserod

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

IBS-C and IBS With Mixed Bowel Habits

Conditions

IBS-C and IBS With Mixed Bowel Habits

Trial Timeline

Apr 1, 2004 → Jun 1, 2005

NCT ID

NCT00142987

About Tegaserod

Tegaserod is a approved stage product being developed by Novartis for IBS-C and IBS With Mixed Bowel Habits. The current trial status is completed. This product is registered under clinical trial identifier NCT00142987. Target conditions include IBS-C and IBS With Mixed Bowel Habits.

What happened to similar drugs?

0 of 4 similar drugs in IBS-C and IBS With Mixed Bowel Habits were approved

Approved (0) Terminated (0) Active (4)

🔄linaclotide + PlaceboAstellas PharmaPhase 3

🔄Placebo + LinaclotideAstraZenecaPhase 3

🔄TenapanorArdelyxPhase 3

🔄Tenapanor 50 MG + Tenapanor 25 mg bid + PlaceboArdelyxPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00511771	Pre-clinical	Completed	—	—	Irritable Bowel Syndrome With Constipation
NCT00414024	Phase 3	Terminated	Feb 1, 2007	May 1, 2007	Opioid-induced Constipation
NCT00390975	Approved	Terminated	Jan 1, 2007	Mar 1, 2007	Gastroparesis
NCT00399659	Phase 3	Terminated	Nov 1, 2006	Apr 1, 2007	Opioid-induced Constipation
NCT00365820	Phase 2/3	Terminated	Jul 1, 2006	Apr 1, 2007	Constipation
NCT00348634	Approved	Terminated	Jul 1, 2006	Apr 1, 2007	Chronic Constipation
NCT00171457	Phase 3	Completed	Apr 1, 2005	Sep 1, 2006	Heartburn
NCT00171470	Phase 3	Completed	Apr 1, 2005	Aug 1, 2006	Dyspepsia
NCT00139568	Phase 3	Completed	Feb 1, 2005	Oct 1, 2005	Constipation
NCT00563758	Pre-clinical	Terminated	Dec 1, 2004	Feb 1, 2006	Constipation
NCT00563615	Pre-clinical	UNKNOWN	Nov 1, 2004	Oct 1, 2006	Constipation
NCT00171431	Phase 3	Terminated	Nov 1, 2004	May 1, 2006	Constipation Predominant
NCT00232037	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232102	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232089	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Dyspepsia
NCT00142974	Phase 2	Terminated	May 1, 2004	Apr 1, 2005	Diabetic Gastropathy
NCT00142987	Approved	Completed	Apr 1, 2004	Jun 1, 2005	IBS-C and IBS With Mixed Bowel Habits
NCT00149877	Approved	Completed	Apr 1, 2004	Feb 1, 2006	Chronic Constipation
NCT00141089	Phase 3	Completed	Mar 1, 2004	Feb 1, 2005	Chronic Constipation
NCT00171483	Phase 3	Completed	Jan 1, 2004	Apr 1, 2005	Gastroesophageal Reflux Disease (GERD)

Competing Products

6 competing products in IBS-C and IBS With Mixed Bowel Habits

See all competitors

Product	Company	Stage	Hype Score
linaclotide + placebo	Astellas Pharma	Phase 2	35
linaclotide + Placebo	Astellas Pharma	Phase 3	40
Placebo + Linaclotide	AstraZeneca	Phase 3	40
Tenapanor	Ardelyx	Phase 3	41
Tenapanor 50 MG + Tenapanor 25 mg bid + Placebo	Ardelyx	Phase 3	41
Tenapanor + Placebo	Ardelyx	Phase 2	36